AGM
TVRD

Alpine Global Management’s Tvardi Therapeutics TVRD Stock Holding History

Alpine Global Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-945
Closed -$96.3K – 257
2023
Q2 		$96.3K Buy
+945
New +$130K 0.03% 174
2022
Q1 		– Sell
-287
Closed -$126K – 753
2021
Q4 		$126K Buy
+287
New +$144K 0.02% 595

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Alpine Global Management's TVRD Position: Q3 2023 in Review

Alpine Global Management sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 945 shares — an estimated $96.3K sold.

Alpine Global Management first reported a position in TVRD in Q4 2021 and held it in 2 quarters. The position peaked at $126K in Q4 2021. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • Alpine Global Management reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alpine Global Management sold 945 Tvardi Therapeutics shares in Q3 2023, an estimated $96.3K.
  • Alpine Global Management first reported a position in Tvardi Therapeutics in Q4 2021 and held it in 2 quarters.
  • Alpine Global Management's Tvardi Therapeutics position peaked at $126K in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Alpine Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.